Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real Assets
Further step in Bayer’s efforts to sharpen focus on core business (Source: Bayer Company News)
Source: Bayer Company News - November 29, 2019 Category: Pharmaceuticals Source Type: news
Bayer submits application to EMA for use of rivaroxaban in children with venous thromboembolism (for specialized target groups only)
Adding treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosis / Submission based on results from phase 3 EINSTEIN-Jr. study showing convincing efficacy and safety profile for rivaroxaban in children with VTE / An oral liquid formulation of rivaroxaban that does not require injections and regular monitoring was developed to facilitate pediatric administration / Patent extension in Europe of six months will be applied for once the procedure is completed (Source: Bayer Company News)
Source: Bayer Company News - November 25, 2019 Category: Pharmaceuticals Source Type: news
Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint (for specialized target groups only)
Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart failure (Source: Bayer Company News)
Source: Bayer Company News - November 18, 2019 Category: Pharmaceuticals Source Type: news
Bayer refinances 1.75 billion euro hybrid bond
New issue of two tranches with a non-call period of 5.5 and 8 years combined with a tender offer for Bayer’s existing hybrid bond (Source: Bayer Company News)
Source: Bayer Company News - November 7, 2019 Category: Pharmaceuticals Source Type: news
Bayer invests USD 50 Million in eGenesis Series B financing round
Investment to support development of human-compatible xeno organs to address the global organ shortage crisis / eGenesis with lead program in kidney transplantation (Source: Bayer Company News)
Source: Bayer Company News - November 7, 2019 Category: Pharmaceuticals Source Type: news
Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health
Group sales increase by 5.4 percent (Fx& portfolio adj.) to 9.830 billion euros / EBITDA before special items advances by 7.5 percent to 2.291 billion euros / Crop Science reports higher sales and substantial earnings growth / Pharmaceuticals increases sales – earnings decline due to one-time income in prior year / Consumer Health posts growth in sales (Fx& portfolio adj.) and earnings / Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year / Core earnings per share up by 6.4 percent to 1.16 euros / Group outlook confirmed and aligned to continuing operations (S...
Source: Bayer Company News - October 30, 2019 Category: Pharmaceuticals Source Type: news
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients (for specialized target groups only)
A new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTE (Source: Bayer Company News)
Source: Bayer Company News - October 14, 2019 Category: Pharmaceuticals Source Type: news
Ertharin Cousin to become member of Bayer AG Supervisory Board
International expert in the area of nutrition and agriculture / Cousin succeeds Thomas Ebeling, who stepped down at the end of September (Source: Bayer Company News)
Source: Bayer Company News - October 1, 2019 Category: Pharmaceuticals Source Type: news
Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer (for specialized target groups only)
79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications(1,2) / Similar ORR of 75% in patients with brain metastases(1), adding to the previously reported evidence for larotrectinib’s activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved; median duration of response (mDOR) of nearly three years(1) / Largest dataset with longest follow-up of any TRK inhibitor illustrates favor...
Source: Bayer Company News - September 28, 2019 Category: Pharmaceuticals Source Type: news
Vitrakvi ® (larotrectinib) receives first tumor-agnostic approval in EU (for specialized target groups only)
Precision oncology treatment Vitrakvi ® (larotrectinib) approved for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Vitrakvi, which was exclusively designed to treat TRK fusion cancer, is the first therapy in the EU with a tumor-agno stic indication / Larotrectinib provides high response rates and durable responses in adults and children with TRK fusion cancer, including primary CNS tumors and brain metastases / In studies, larotrectinib demonstrated an overall response rate of 72% including 16% complete responses, with...
Source: Bayer Company News - September 23, 2019 Category: Pharmaceuticals Source Type: news
Bayer reduces size of Board of Management from seven to five members
(Source: Bayer Company News)
Source: Bayer Company News - September 10, 2019 Category: Pharmaceuticals Source Type: news
Xarelto & #8482; 2.5 mg plus aspirin recommended for patients at high risk of heart attacks, strokes and death due to chronic coronary syndromes
Clinical practice guidelines from the European Society of Cardiology (ESC) recommend Xarelto vascular dose (2.5 mg twice daily) plus aspirin low dose once daily in the management of patients with chronic coronary syndromes (CCS) as well as for patients with diabetes and lower extremity arterial disease / New guidelines include a change in nomenclature from‘stable coronary artery disease’ to‘chronic coronary syndromes’ to better reflect the continuous high risk of heart attacks, strokes and death within this patient population (Source: Bayer Company News)
Source: Bayer Company News - September 2, 2019 Category: Pharmaceuticals Source Type: news
Bayer to sell its Animal Health business unit to Elanco for 7.6 billion U.S. dollars
Exit of Animal Health business completes the series of portfolio measures initiated by Bayer in November 2018 ahead of announced schedule / Enhances Bayer’s focus as a global leader in life sciences (Source: Bayer Company News)
Source: Bayer Company News - August 20, 2019 Category: Pharmaceuticals Source Type: news
Bayer to sell its Animal Health business unit to Elanco
for 7.6 billion U.S. dollars
Exit of Animal Health business completes the series of portfolio measures initiated by Bayer in November 2018 ahead of announced schedule / Enhances Bayer’s focus as a global leader in life sciences (Source: Bayer Company News)
Source: Bayer Company News - August 20, 2019 Category: Pharmaceuticals Source Type: news
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year / BlueRock Therapeutics to continue to operate as an independent company (Source: Bayer Company News)
Source: Bayer Company News - August 8, 2019 Category: Pharmaceuticals Source Type: news
